肺表面活性物质制剂开塞肺的药效实验

Evaluationofeficacyofpulmonarysurfactantinpremature

为评价以小牛肺为原料制备的肺表面活性物质（ＰＳ）制剂开塞肺的药效，对７８只早产兔ＰＳ缺乏呼吸窘迫综合征模型进行了动物实验，以观察早产兔对小牛肺ＰＳ制剂（简称开塞肺）的反应，并与德国的同类制剂（Ａｌｖｅｏｆａｃｔ）作了对比。结果，给药后各治疗组早产兔肺开放压显著降低（Ｐ＜０．０１），呼气相Ｖ５、静态顺应性及肺泡扩张显著改善（Ｐ＜０．０１）。提示开塞肺对呼吸窘迫综合征是一有效制剂，最适剂量约为５０～１００ｍｇ／ｋｇ。其效果与德国制剂Ａｌｖｅｏｆａｃｔ比较，差异无显著意义。

Weexaminedtheeficacyanddose-dependentresponseofCalsurfpulmonarysurfac-tantpreparationfromcalflunglavagefluidonrespiratorydistresssyndrome(RDS)in78prematurerabbitsandcomparedwithAlveofact(pulmonarysurfactantfromBoehringerIngelheim,Germany).TheanimalsingroupstreatedwitheitherCalsurforAlveofacthadsignificantlylowlungopeningpressure,significantlyincreasedV5onexpiratoryphase,improvedstaticcomplianceandimprovedexpansionoflungalveolicomparedwiththoseincontrolgroup(P<0.01).TheresultsofthisstudydemonstratedthatCalsurfwasanefectivepreparationforreplacementtherapyofRDSandtheap-propriatedoseofCalsurfwasabout50～100mg/kg.TheeficacyofCalsurfandAlveofactwasnotsignificantlydiferent.